CVS Health announced Wednesday that it plans to divide its $117 billion healthcare business into two independent, publicly traded companies, separating its retail pharmacy operations from its insurance and healthcare services divisions. The move marks a significant reversal of the company’s long-running strategy of combining multiple areas of the healthcare industry under one corporate umbrella. The proposed restructuring follows a comprehensive review by the company’s board of directors, with management confirming that the partition will separate its neighborhood drugstores and clinical sites from its insurance carrier and prescription benefits manager. Under the new operational division, stock holders are slated to receive shares in both independent corporate entities via a tax-free distribution, with the complete corporate split projected to wrap up during the initial half of 2028.
The primary organization will continue operating under the CVS Health moniker, maintaining ownership of health insurance firm Aetna, prescription benefit platform CVS Caremark, primary care provider Oak Street Health, home health service Signify Health, and dedicated specialty medication units. David Joyner will remain at the helm of this parent organization as chief executive officer. Meanwhile, the newly created entity, operating as CVS Pharmacy, will be governed by current group president Prem Shah as its new leader. This standalone retail division will encompass roughly 9,000 storefront pharmacies, walk-in MinuteClinic locations, mail-service drug distribution networks, and digital healthcare platforms.
This corporate division reverses major historic transactions, including the pharmacy benefit manager merger with Caremark in 2007 and the $69 billion acquisition of Aetna in 2018. Addressing the strategic turn, Joyner remarked, “We’re basically taking what I believe is one great company and making it two”. Leadership noted that cross-company products and established consumer services built over the last two decades will not be abandoned during the transition. Instead, Joyner explained that “The unique products that we’ve built over the last, you know, 20 years are things that are going to be preserved in commercial agreements between the two organizations. So we don’t need the integration of in an operating structure”.
Market analysts view the surprise corporate split as a clear pivot away from the conglomerate model toward focused operational structures. The decision also follows heightened pressure from lawmakers and state regulators aiming to restrict single corporate entities from simultaneously managing drug benefits while owning retail and mail-order pharmacies. The corporate announcement arrived alongside the company’s third-quarter earnings publication, where CVS raised its fiscal year revenue guidance to at least $420 billion despite ongoing headwinds across the broader healthcare sector.
Editorial credit: Jonathan Weiss / Shutterstock.com